ChromaDex (NASDAQ:CDXC) Price Target Raised to $8.00

ChromaDex (NASDAQ:CDXC) had its price target lifted by HC Wainwright from $6.00 to $8.00 in a report issued on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS and FY2025 earnings at $0.21 EPS.

ChromaDex Price Performance

Shares of NASDAQ:CDXC opened at $6.99 on Monday. ChromaDex has a 1 year low of $1.32 and a 1 year high of $7.08. The company has a market capitalization of $530.77 million, a PE ratio of 699.00 and a beta of 1.88. The business has a fifty day moving average price of $3.70 and a two-hundred day moving average price of $3.28.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The company had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter in the prior year, the business earned ($0.01) earnings per share. Sell-side analysts anticipate that ChromaDex will post 0.01 earnings per share for the current year.

Insider Buying and Selling

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ChromaDex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. OneDigital Investment Advisors LLC raised its position in shares of ChromaDex by 5.5% in the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock valued at $217,000 after purchasing an additional 3,097 shares during the period. Miracle Mile Advisors LLC bought a new stake in ChromaDex during the 2nd quarter valued at $27,000. The Manufacturers Life Insurance Company purchased a new stake in shares of ChromaDex during the second quarter worth $31,000. Merriman Wealth Management LLC bought a new position in shares of ChromaDex in the second quarter worth $32,000. Finally, Lazard Asset Management LLC purchased a new position in shares of ChromaDex in the first quarter valued at $43,000. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.